These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8803917)

  • 41. The blood-retinal barrier in chloroquine retinopathy.
    Raines MF; Bhargava SK; Rosen ES
    Invest Ophthalmol Vis Sci; 1989 Aug; 30(8):1726-31. PubMed ID: 2759787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular toxicity of hydroxychloroquine.
    Yam JC; Kwok AK
    Hong Kong Med J; 2006 Aug; 12(4):294-304. PubMed ID: 16912357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RE: Author reply:
    Martínez-Costa L; Trentini FJ; Ibañez MV; Murcia-Bello C; Epifanio I; Verdejo-Gimeno C; Beltrán-Catalán E; Marco-Ventura P
    Can J Ophthalmol; 2014 Jun; 49(3):308. PubMed ID: 24862783
    [No Abstract]   [Full Text] [Related]  

  • 44. [Ophthalmologic monitoring in chloroquine therapy].
    Eggers I; Krastel H
    Klin Monbl Augenheilkd; 1998 Sep; 213(3):aA10. PubMed ID: 9793906
    [No Abstract]   [Full Text] [Related]  

  • 45. [Chloroquine retinopathy: avoidable by individualized daily dosing].
    Ochsendorf FR; Runne U; Goerz G; Zrenner E
    Dtsch Med Wochenschr; 1993 Dec; 118(51-52):1895-8. PubMed ID: 8287780
    [No Abstract]   [Full Text] [Related]  

  • 46. [Antimalarial's retinopaty remains a current threat].
    Chiffoleau A; Guillet A; Zanlonghi X; Jolliet P
    Presse Med; 2009 Apr; 38(4):662-3. PubMed ID: 19135848
    [No Abstract]   [Full Text] [Related]  

  • 47. Dose relationships in patients with early chloroquine retinopathy.
    Easterbrook M
    J Rheumatol; 1987 Jun; 14(3):472-5. PubMed ID: 3625628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report.
    Wei LC; Chen SN; Ho CL; Kuo YH; Ho JD
    Chang Gung Med J; 2001 May; 24(5):329-34. PubMed ID: 11480331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retinal toxicity due to antimalarials: frequency and risk factors.
    Palma Sánchez D; Rubio Velazquez E; Soro Marín S; Reyes García R
    Reumatol Clin; 2013; 9(5):259-62. PubMed ID: 23707434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Ophthalmological monitoring protocol for patients treated with long-term antimalarials or vigabatrin].
    Ingster-Moati I; Orssaud C
    J Fr Ophtalmol; 2009 Jan; 32(1):83-8. PubMed ID: 19515321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimalarial treatment of rheumatoid arthritis: 1985 status.
    Rynes RI
    J Rheumatol; 1985 Aug; 12(4):657-9. PubMed ID: 4057186
    [No Abstract]   [Full Text] [Related]  

  • 52. Current practice in antimalarial drug prescribing in rheumatoid arthritis.
    Bellamy N; Brooks PM
    J Rheumatol; 1986 Jun; 13(3):551-5. PubMed ID: 3735276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydroxychloroquine-induced retinopathy: a dermatologic perspective.
    Tripp JM; Maibach HI
    Am J Clin Dermatol; 2006; 7(3):171-5. PubMed ID: 16734504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of color vision defects in chloroquine retinopathy.
    Vu BL; Easterbrook M; Hovis JK
    Ophthalmology; 1999 Sep; 106(9):1799-803; discussion 1804. PubMed ID: 10485553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Update on recommendations for screening for hydroxychloroquine retinopathy].
    Couturier A; Giocanti-Aurégan A; Dupas B; Girmens JF; Le Mer Y; Massamba N; Barreau E; Audo I;
    J Fr Ophtalmol; 2017 Nov; 40(9):793-800. PubMed ID: 29054477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Diagnostic methods for chloroquine diphosphate induced retinopathy in systemic lupus erythematosus].
    Rodrigues LD; Shinjo SK; Oyamada MK; Serracarbassa PD; Takahashi WY; Borba EF; Bonfá ES; Nakashima Y
    Arq Bras Oftalmol; 2009; 72(3):313-20. PubMed ID: 19668959
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
    Chacón-Dulcey V; López-Labady J; Villarroel-Dorrego M; Frías J; Tirado W; González N; Pérez Alfonzo R
    Lupus; 2020 Jun; 29(7):761-766. PubMed ID: 32362181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening for antimalarial toxicity.
    Easterbrook M
    Can J Ophthalmol; 1993 Apr; 28(2):51-2. PubMed ID: 8508335
    [No Abstract]   [Full Text] [Related]  

  • 59. Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine.
    Yusuf IH; Ledingham JM; MacPhie E; Lotery AJ; Galloway J
    Rheumatology (Oxford); 2019 Jan; 58(1):3-4. PubMed ID: 29529306
    [No Abstract]   [Full Text] [Related]  

  • 60. Ophthalmologic monitoring for antimalarial toxicity.
    Sfikakis PP; Mavrikakis M
    J Rheumatol; 2004 May; 31(5):1011-2; author reply 1012. PubMed ID: 15124272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.